Symbols / CABA
CABA Chart
About
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. Its lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, non-renal systemic lupus erythematosus, relapsing and progressive multiple sclerosis, mucocutaneous and mucosal pemphigus vulgaris (PV), systemic sclerosis, and generalized myasthenia gravis. The company also develops DSG3-CAART, a CAAR T cell therapy that is in Phase 1 clinical trial for the treatment of mucosal PV; and MuSK-CAART, an investigational cell therapy in Phase 1 trial for treating patients with anti-muscle-specific kinase (MuSK) antibody positive myasthenia gravis. It has collaborations with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; Autolus Holdings (UK) Limited; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 330.19M |
| Enterprise Value | 182.56M | Income | -158.52M | Sales | — |
| Book/sh | 1.45 | Cash/sh | 1.66 | Dividend Yield | — |
| Payout | 0.00% | Employees | 148 | IPO | — |
| P/E | — | Forward P/E | -2.05 | PEG | — |
| P/S | — | P/B | 2.37 | P/C | — |
| EV/EBITDA | -1.13 | EV/Sales | — | Quick Ratio | 3.50 |
| Current Ratio | 3.60 | Debt/Eq | 18.48 | LT Debt/Eq | — |
| EPS (ttm) | -2.40 | EPS next Y | -1.68 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-30 | ROA | -51.82% |
| ROE | -101.06% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 96.27M |
| Shs Float | 70.98M | Short Float | 19.73% | Short Ratio | 4.77 |
| Short Interest | — | 52W High | 3.67 | 52W Low | 0.99 |
| Beta | 3.30 | Avg Volume | 2.91M | Volume | 263.65K |
| Target Price | $13.12 | Recom | Strong_buy | Prev Close | $3.29 |
| Price | $3.43 | Change | 4.26% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$13.13
Mean price target
2. Current target
$3.74
Latest analyst target
3. DCF / Fair value
$-13.76
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$3.74
Low
$2.00
High
$30.00
Mean
$13.13
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-10-31 | main | Cantor Fitzgerald | Overweight → Overweight | $30 |
| 2025-10-10 | reit | HC Wainwright & Co. | Buy → Buy | $16 |
| 2025-09-05 | reit | Cantor Fitzgerald | Overweight → Overweight | $15 |
| 2025-08-14 | main | Citigroup | Buy → Buy | $10 |
| 2025-08-08 | main | Wells Fargo | Equal-Weight → Equal-Weight | $2 |
| 2025-08-08 | main | Guggenheim | Buy → Buy | $15 |
| 2025-06-11 | reit | HC Wainwright & Co. | Buy → Buy | $25 |
| 2025-05-16 | main | Citigroup | Buy → Buy | $13 |
| 2025-05-16 | main | Guggenheim | Buy → Buy | $25 |
| 2025-05-15 | main | Guggenheim | Buy → Buy | $25 |
| 2025-04-01 | main | Wells Fargo | Equal-Weight → Equal-Weight | $3 |
| 2025-04-01 | reit | Guggenheim | Buy → Buy | $23 |
| 2025-04-01 | main | UBS | Buy → Buy | $7 |
| 2025-04-01 | main | Morgan Stanley | Overweight → Overweight | $22 |
| 2025-04-01 | reit | HC Wainwright & Co. | Buy → Buy | $25 |
| 2025-02-18 | reit | HC Wainwright & Co. | Buy → Buy | $25 |
| 2025-01-17 | reit | HC Wainwright & Co. | Buy → Buy | $25 |
| 2024-12-20 | down | Evercore ISI Group | Outperform → In-Line | $6 |
| 2024-12-19 | down | Wells Fargo | Overweight → Equal-Weight | $6 |
| 2024-11-18 | reit | HC Wainwright & Co. | Buy → Buy | $25 |
- Why Cabaletta Bio (CABA) Is Up 41.3% After FDA Clears Automated CAR T Manufacturing Platforms - Yahoo Finance Fri, 23 Jan 2026 08
- What Makes Cabaletta Bio, Inc. (CABA) a Strong Momentum Stock: Buy Now? - Nasdaq Fri, 30 Jan 2026 08
- Cabaletta Bio Stock (CABA) Opinions on Insider Buying and Clinical Updates - Quiver Quantitative Fri, 23 Jan 2026 08
- Here’s why Jacob Funds established a position in Cabaletta Bio (CABA) - MSN Wed, 25 Feb 2026 04
- Millennium Group (CABA) jointly reports 5.3% holding of 5.13M shares - Stock Titan Wed, 18 Feb 2026 22
- Assessing Cabaletta Bio (CABA) Valuation After FDA Clearance For Automated CAR T Manufacturing - simplywall.st Sat, 24 Jan 2026 08
- Cabaletta Bio: Do You Buy With The Insiders? (NASDAQ:CABA) - Seeking Alpha ue, 27 Jan 2026 08
- CABA Stock: Cantor Fitzgerald Raises Price Target to $30, Mainta - GuruFocus Fri, 31 Oct 2025 07
- Cabaletta Bio’s SWOT analysis: CAR-T innovator’s stock faces market skepticism - Investing.com Wed, 17 Sep 2025 07
- Is Cabaletta Bio (CABA) Outperforming Other Medical Stocks This Year? - Yahoo Finance ue, 27 Jan 2026 08
- Cabaletta Bio (Nasdaq: CABA) offers webcasts across Nov–Dec conferences; 30-day replays - Stock Titan ue, 04 Nov 2025 08
- $CABA stock is up 28% today. Here's what we see in our data. - Quiver Quantitative hu, 22 Jan 2026 08
- Guggenheim reiterates Buy rating on Cabaletta Bio stock, citing commercial plan - Investing.com ue, 27 Jan 2026 08
- Cabaletta Bio (CABA): Assessing Valuation After RESET-PV Trial Results Spark Investor Interest - Yahoo Finance Mon, 13 Oct 2025 07
- Cabaletta Bio (CABA) Upgraded to Buy: Here's Why - Yahoo Finance Mon, 11 Aug 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 11061 | 25261 | — | Purchase at price 2.28 per share. | SIMON MARK | Director | — | 2026-01-21 00:00:00 | D |
| 1 | 45000 | 100778 | — | Purchase at price 2.24 per share. | NICHTBERGER STEVEN | Chief Executive Officer | — | 2026-01-21 00:00:00 | D |
| 2 | 22725 | 50322 | — | Purchase at price 2.21 per share. | TOMASELLO SHAWN CLINE | Director | — | 2026-01-21 00:00:00 | I |
| 3 | 8800 | 19888 | — | Purchase at price 2.26 per share. | CHANG DAVID J. M.D. | Officer | — | 2026-01-21 00:00:00 | D |
| 4 | 4405 | 9982 | — | Purchase at price 2.27 per share. | BOLLARD CATHERINE M.D. | Director | — | 2026-01-21 00:00:00 | D |
| 5 | 11312 | 24763 | — | Purchase at price 2.19 per share. | BINDER GWENDOLYN | Officer | — | 2026-01-21 00:00:00 | D |
| 6 | 6600 | 14979 | — | Purchase at price 2.27 per share. | GERARD MICHAEL | General Counsel | — | 2026-01-21 00:00:00 | D |
| 7 | 22170 | 50215 | — | Purchase at price 2.26 per share. | GAVEL STEVE | Officer | — | 2026-01-21 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -113.41M | -66.25M | -52.96M | -45.58M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -115.86M | -67.67M | -52.98M | -46.29M |
| ReconciledDepreciation | 1.71M | 1.43M | 1.18M | 733.00K |
| EBITDA | -113.41M | -66.25M | -52.96M | -45.58M |
| EBIT | -115.12M | -67.67M | -54.14M | -46.31M |
| NetInterestIncome | 9.28M | 6.99M | 1.16M | 24.00K |
| InterestExpense | 748.00K | 0.00 | ||
| InterestIncome | 10.03M | 6.99M | 1.16M | 24.00K |
| NormalizedIncome | -115.86M | -67.67M | -52.98M | -46.29M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -115.86M | -67.67M | -52.98M | -46.29M |
| TotalExpenses | 125.14M | 74.66M | 54.14M | 46.31M |
| TotalOperatingIncomeAsReported | -125.14M | -74.66M | -54.14M | -46.31M |
| DilutedAverageShares | 49.51M | 40.95M | 29.27M | 25.72M |
| BasicAverageShares | 49.51M | 39.19M | 29.27M | 25.72M |
| DilutedEPS | -2.34 | -1.65 | -1.81 | -1.80 |
| BasicEPS | -2.34 | -1.65 | -1.81 | -1.80 |
| DilutedNIAvailtoComStockholders | -115.86M | -67.67M | -52.98M | -46.29M |
| NetIncomeCommonStockholders | -115.86M | -67.67M | -52.98M | -46.29M |
| NetIncome | -115.86M | -67.67M | -52.98M | -46.29M |
| NetIncomeIncludingNoncontrollingInterests | -115.86M | -67.67M | -52.98M | -46.29M |
| NetIncomeContinuousOperations | -115.86M | -67.67M | -52.98M | -46.29M |
| PretaxIncome | -115.86M | -67.67M | -52.98M | -46.29M |
| NetNonOperatingInterestIncomeExpense | 9.28M | 6.99M | 1.16M | 24.00K |
| InterestExpenseNonOperating | 748.00K | 0.00 | ||
| InterestIncomeNonOperating | 10.03M | 6.99M | 1.16M | 24.00K |
| OperatingIncome | -125.14M | -74.66M | -54.14M | -46.31M |
| OperatingExpense | 125.14M | 74.66M | 54.14M | 46.31M |
| ResearchAndDevelopment | 97.20M | 55.42M | 39.30M | 32.49M |
| SellingGeneralAndAdministration | 27.94M | 19.24M | 14.84M | 13.82M |
| GeneralAndAdministrativeExpense | 27.94M | 19.24M | 14.84M | 13.82M |
| OtherGandA | 27.94M | 19.24M | 14.84M | 13.82M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 50.74M | 46.38M | 29.45M | 28.93M |
| ShareIssued | 50.74M | 46.38M | 29.45M | 28.93M |
| TotalDebt | 15.60M | 5.02M | 5.14M | 0.00 |
| TangibleBookValue | 152.34M | 236.20M | 104.52M | 117.96M |
| InvestedCapital | 152.34M | 236.20M | 104.52M | 117.96M |
| WorkingCapital | 139.59M | 228.50M | 99.34M | 116.16M |
| NetTangibleAssets | 152.34M | 236.20M | 104.52M | 117.96M |
| CapitalLeaseObligations | 15.60M | 5.02M | 5.14M | 0.00 |
| CommonStockEquity | 152.34M | 236.20M | 104.52M | 117.96M |
| TotalCapitalization | 152.34M | 236.20M | 104.52M | 117.96M |
| TotalEquityGrossMinorityInterest | 152.34M | 236.20M | 104.52M | 117.96M |
| StockholdersEquity | 152.34M | 236.20M | 104.52M | 117.96M |
| GainsLossesNotAffectingRetainedEarnings | 0.00 | 39.00K | -47.00K | 0.00 |
| OtherEquityAdjustments | 39.00K | -47.00K | ||
| RetainedEarnings | -349.10M | -233.24M | -165.56M | -112.59M |
| AdditionalPaidInCapital | 501.44M | 469.40M | 270.13M | 230.54M |
| CapitalStock | 1.00K | 0.00 | 0.00 | 0.00 |
| CommonStock | 1.00K | 0.00 | 0.00 | 0.00 |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 32.71M | 17.45M | 12.45M | 8.38M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 5.62M | 1.46M | 2.96M | 0.00 |
| LongTermDebtAndCapitalLeaseObligation | 5.62M | 1.46M | 2.96M | 0.00 |
| LongTermCapitalLeaseObligation | 5.62M | 1.46M | 2.96M | 0.00 |
| CurrentLiabilities | 27.09M | 15.99M | 9.49M | 8.38M |
| OtherCurrentLiabilities | 40.00K | 40.00K | 39.00K | 54.00K |
| CurrentDebtAndCapitalLeaseObligation | 9.97M | 3.56M | 2.18M | |
| CurrentCapitalLeaseObligation | 9.97M | 3.56M | 2.18M | 0.00 |
| PensionandOtherPostRetirementBenefitPlansCurrent | 8.31M | 5.20M | 3.52M | 2.98M |
| PayablesAndAccruedExpenses | 8.76M | 7.19M | 3.76M | 5.35M |
| CurrentAccruedExpenses | 3.83M | 2.65M | 1.29M | 3.02M |
| Payables | 4.92M | 4.55M | 2.46M | 2.33M |
| AccountsPayable | 4.92M | 4.55M | 2.46M | 2.33M |
| TotalAssets | 185.05M | 253.65M | 116.97M | 126.34M |
| TotalNonCurrentAssets | 18.37M | 9.16M | 8.13M | 1.79M |
| OtherNonCurrentAssets | 2.29M | 1.71M | 565.00K | 357.00K |
| NetPPE | 16.08M | 7.45M | 7.57M | 1.44M |
| AccumulatedDepreciation | -5.51M | -3.79M | -2.37M | -1.19M |
| GrossPPE | 21.58M | 11.25M | 9.94M | 2.63M |
| Leases | 113.00K | 113.00K | 113.00K | 57.00K |
| OtherProperties | 21.00M | 10.80M | 9.49M | 2.24M |
| MachineryFurnitureEquipment | 473.00K | 330.00K | 330.00K | 330.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 166.68M | 244.49M | 108.83M | 124.54M |
| OtherCurrentAssets | 2.71M | 3.24M | 2.29M | 2.32M |
| PrepaidAssets | 2.32M | |||
| CashCashEquivalentsAndShortTermInvestments | 163.96M | 241.25M | 106.55M | 122.22M |
| OtherShortTermInvestments | 0.00 | 48.01M | 24.94M | 0.00 |
| CashAndCashEquivalents | 163.96M | 193.24M | 81.61M | 122.22M |
| CashEquivalents | 192.50M | 81.61M | ||
| CashFinancial | 743.00K |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -90.43M | -54.24M | -48.83M | -35.27M |
| RepaymentOfDebt | -897.00K | 0.00 | ||
| IssuanceOfCapitalStock | 10.88M | 185.20M | 32.85M | 48.25M |
| CapitalExpenditure | -2.21M | -687.00K | -2.45M | -1.17M |
| InterestPaidSupplementalData | 748.00K | 0.00 | ||
| EndCashPosition | 163.96M | 193.24M | 81.61M | 122.22M |
| BeginningCashPosition | 193.24M | 81.61M | 122.22M | 101.43M |
| EffectOfExchangeRateChanges | -20.00K | 0.00 | ||
| ChangesInCash | -29.26M | 111.63M | -40.62M | 20.79M |
| FinancingCashFlow | 11.68M | 187.63M | 32.98M | 48.90M |
| CashFlowFromContinuingFinancingActivities | 11.68M | 187.63M | 32.98M | 48.90M |
| ProceedsFromStockOptionExercised | 1.70M | 2.43M | 127.00K | 650.00K |
| NetCommonStockIssuance | 10.88M | 185.20M | 32.85M | 48.25M |
| CommonStockIssuance | 10.88M | 185.20M | 32.85M | 48.25M |
| NetIssuancePaymentsOfDebt | -897.00K | 0.00 | ||
| NetLongTermDebtIssuance | -897.00K | 0.00 | ||
| LongTermDebtPayments | -897.00K | 0.00 | ||
| InvestingCashFlow | 47.29M | -22.45M | -27.22M | 6.00M |
| CashFlowFromContinuingInvestingActivities | 47.29M | -22.45M | -27.22M | 6.00M |
| NetInvestmentPurchaseAndSale | 49.50M | -21.76M | -24.76M | 7.17M |
| SaleOfInvestment | 49.50M | 62.50M | 25.00M | 7.17M |
| PurchaseOfInvestment | 0.00 | -84.26M | -49.76M | 0.00 |
| NetPPEPurchaseAndSale | -2.21M | -687.00K | -2.45M | -1.17M |
| PurchaseOfPPE | -2.21M | -687.00K | -2.45M | -1.17M |
| OperatingCashFlow | -88.22M | -53.55M | -46.38M | -34.11M |
| CashFlowFromContinuingOperatingActivities | -88.22M | -53.55M | -46.38M | -34.11M |
| ChangeInWorkingCapital | 1.61M | 101.00K | -4.30M | 5.58M |
| ChangeInOtherCurrentLiabilities | -3.29M | -2.46M | -2.91M | 0.00 |
| ChangeInOtherCurrentAssets | -584.00K | -1.14M | -208.00K | -58.00K |
| ChangeInPayablesAndAccruedExpense | 4.96M | 4.66M | -1.21M | 3.08M |
| ChangeInAccruedExpense | 3.95M | 2.98M | -1.19M | 2.11M |
| ChangeInPayable | 1.01M | 1.68M | -28.00K | 975.00K |
| ChangeInAccountPayable | 1.01M | 1.68M | -28.00K | 975.00K |
| ChangeInPrepaidAssets | 528.00K | -954.00K | 32.00K | 2.55M |
| OtherNonCashItems | 6.34M | 2.48M | 3.04M | |
| StockBasedCompensation | 19.46M | 11.34M | 6.90M | 5.80M |
| AmortizationOfSecurities | -1.53M | -1.22M | -223.00K | 62.00K |
| DepreciationAmortizationDepletion | 1.71M | 1.43M | 1.18M | 733.00K |
| DepreciationAndAmortization | 1.71M | 1.43M | 1.18M | 733.00K |
| Depreciation | 1.71M | 1.43M | 1.18M | 733.00K |
| OperatingGainsLosses | 38.00K | |||
| NetForeignCurrencyExchangeGainLoss | 38.00K | 0.00 | ||
| NetIncomeFromContinuingOperations | -115.86M | -67.67M | -52.98M | -46.29M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for CABA
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|